Abstract
Maintenance olaparib monotherapy for platinum-sensitive relapsed ovarian cancer in patients without a germline BRCA1/BRCA2 mutation: Secondary safety results from the phase IIIb OPINION study (128)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
